<table>
<thead>
<tr>
<th>PSCs</th>
<th>ESCs/iPSCs</th>
<th>Media condition</th>
<th>Transgene</th>
<th>Teratoma formation</th>
<th>Self-renewal X-Chromosome status</th>
<th>Expression of pluripotency markers</th>
<th>Potential of chimera formation</th>
<th>State of pluripotency</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mink</td>
<td>ESCs</td>
<td></td>
<td>Yes (ESCs from Morula &amp; ICM)</td>
<td>Yes (ESCs from Morula &amp; ICM)</td>
<td>Pre-inactivation (ESCs from Morula &amp; ICM)</td>
<td></td>
<td></td>
<td></td>
<td>(Sukoyan et al., 1993)</td>
</tr>
<tr>
<td>Rabbit</td>
<td>ESCs</td>
<td>KSR, FGF2</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Primed</td>
<td></td>
<td></td>
<td>(Osteil et al., 2016)</td>
</tr>
<tr>
<td></td>
<td>ESCs and iPSCs</td>
<td>Forskolin, CH, LIF</td>
<td>hOct ¾</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Naive-like</td>
<td></td>
<td>(Honsho et al., 2015)</td>
</tr>
<tr>
<td>Porcine</td>
<td>ESCs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Li et al., 2003)</td>
</tr>
<tr>
<td></td>
<td>ESCs</td>
<td>MEF, hFGF2, hLIF, ROCKi, FBS/KSR</td>
<td></td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td>(Siriboon et al., 2015)</td>
</tr>
<tr>
<td></td>
<td>iPSCs</td>
<td>LIF, 2i</td>
<td>Oct4, Sox2, Klf4, c-Myc</td>
<td>Yes</td>
<td>Yes</td>
<td>Naive-like</td>
<td></td>
<td></td>
<td>(Telugu et al., 2010)</td>
</tr>
<tr>
<td></td>
<td>iPSCs</td>
<td>MEF, FGF2, LIF, FBS, KSR</td>
<td>Oct4, Sox2, Klf4, c-Myc</td>
<td>Yes</td>
<td>Yes</td>
<td>Primated</td>
<td></td>
<td></td>
<td>(Gao et al., 2014)</td>
</tr>
<tr>
<td>Bovine</td>
<td>ESCs</td>
<td>MEF, BEF, hFGF2, hLIF, FBS</td>
<td></td>
<td></td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td>(Cong et al., 2014)</td>
</tr>
<tr>
<td>Horse</td>
<td>ESCs</td>
<td>MEF, LIF, FBS</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td>(Li et al., 2006)</td>
</tr>
<tr>
<td></td>
<td>ESCs</td>
<td>MEF, LIF, FBS</td>
<td></td>
<td></td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td>(Guest &amp; Allen, 2007)</td>
</tr>
<tr>
<td></td>
<td>iPSCs</td>
<td>MEF, FGF2, LIF, FBS</td>
<td>Oct4, Sox2, Klf4, c-Myc</td>
<td>Yes</td>
<td>Yes</td>
<td>Primated</td>
<td></td>
<td></td>
<td>(Nagy et al., 2011)</td>
</tr>
<tr>
<td>Dog</td>
<td>ESCs</td>
<td>MEF, hFGF2, hLIF, FBS/KSR</td>
<td></td>
<td></td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td>(Vaags et al., 2009)</td>
</tr>
<tr>
<td></td>
<td>iPSCs</td>
<td>MEF, 2i, hFGF2, hLIF, KSR</td>
<td>OCT4, SOX2, NANOG, LIN28</td>
<td>Yes</td>
<td>Yes</td>
<td>Primated</td>
<td></td>
<td></td>
<td>(Koh et al., 2013)</td>
</tr>
<tr>
<td>Cat</td>
<td>ESCs</td>
<td>hFGF, mLIF, KSR, FBS</td>
<td></td>
<td></td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td>(Gómez et al., 2010)</td>
</tr>
</tbody>
</table>

**Table S1: Details of pluripotent stem cells derived and characterized from distinct mammals.** Blank cells denote unavailable and or unclear information on specified details. 2i, 2 inhibitors (MEK inhibitor (PD03259010), GSK3 inhibitor (CHIR99021)); LIF, Leukemia inhibitory factor; ROCKi, RHO-associated protein kinase 1 inhibitor; FGF2, fibroblast growth factor 2; MEF, mouse embryonic fibroblasts; hFGF, human fibroblast growth factor; FBS, Fetal bovine serum; BEF, bovine embryonic fibroblast; EFF, equine fetal fibroblast.

**Reference:**


